Graft Versus Host Disease (GVHD)
Graft Versus Host Disease remains a serious complication following the transplantation of hematopoietic stem cell, with limited treatment options for cases that are refractory to current treatments. At AION Healthspan, we are advancing AION-301, a novel cell-derived immunomodulatory therapy designed to restore immune balance and promote tissue repair.
Early observations from pilot studies are being further explored in collaboration with Stanford Medicine, helping to guide the design of our upcoming clinical trial for GVHD.
Stay connected for trial updates and investigator opportunities.
Sign up for news to stay up to date on our clinical trial plans